Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Helicobacter pylori

Tailored therapy with novel sequential quadruple therapies

Nature Reviews Gastroenterology & Hepatology volume 10, pages 6–8 (2013)Cite this article

Subjects

Treatment success for Helicobacter pylori, a major human pathogen, with popular drug regimens has generally declined to unacceptably low levels. As part of the worldwide effort to identify novel drug regimens that will reliably achieve high levels of success, Tay, Marshall and colleagues report their results with novel multidrug-tailored therapies.

Access through your institution
Buy or subscribe

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Access through your institution

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Tay, C. Y. et al. Helicobacter pylori eradication in Western Australia using novel quadruple therapy combinations. Aliment. Pharmacol. Ther. http://dx.doi.org/10.1111/apt.12089.

  2. Rimbara, E., Fischbach, L. A. & Graham, D. Y. Optimal therapy for Helicobacter pylori infections. Nat. Rev. Gastroenterol. Hepatol. 8, 79–88 (2011).

    Article  CAS  Google Scholar 

  3. Graham, D. Y. & Lu, H. Furazolidone in Helicobacter pylori therapy: misunderstood and often unfairly maligned drug told in a story of French bread. Saudi J. Gastroenterol. 18, 1–2 (2012).

    Article  Google Scholar 

  4. Fischbach, L. A., van, Z. S. & Dickason, J. Meta-analysis: the efficacy, adverse events, and adherence related to first-line anti-Helicobacter pylori quadruple therapies. Aliment. Pharmacol. Ther. 20, 1071–1082 (2004).

    Article  CAS  Google Scholar 

  5. Borody, T. J. et al. Efficacy and safety of rifabutin-containing 'rescue therapy' for resistant Helicobacter pylori infection. Aliment. Pharmacol. Ther. 23, 481–488 (2006).

    Article  CAS  Google Scholar 

  6. Federico, A. et al. Efficacy of 5-day levofloxacin-based concomitant therapy in eradication of Helicobacter pylori infection. Gastroenterology 143, 55–61 (2012).

    Article  CAS  Google Scholar 

  7. Hsu, P. I., Wu, D. C., Wu, J. Y. & Graham, D. Y. Modified sequential Helicobacter pylori therapy: proton pump inhibitor and amoxicillin for 14 days with clarithromycin and metronidazole added as a quadruple (Hybrid) therapy for the final 7 days. Helicobacter 16, 139–145 (2011).

    Article  CAS  Google Scholar 

  8. Uygun, A. et al. Efficacy of a modified sequential therapy including bismuth subcitrate as first-line therapy to eradicate Helicobacter pylori in a Turkish population. Helicobacter 17, 486–490 (2012).

    Article  CAS  Google Scholar 

  9. Saad, R. J., Schoenfeld, P., Kim, H. M. & Chey, W. D. Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection: a meta-analysis. Am. J. Gastroenterol. 101, 488–496 (2006).

    Article  CAS  Google Scholar 

  10. Gisbert, J. P. & Morena, F. Systematic review and meta-analysis: levofloxacin-based rescue regimens after Helicobacter pylori treatment failure. Aliment. Pharmacol. Ther. 23, 35–44 (2006).

    Article  CAS  Google Scholar 

Download references

Acknowledgements

Dr. Graham is supported in part by the Office of Research and Development Medical Research Service Department of Veterans Affairs, Public Health Service grant DK56338, which funds the Texas Medical Center Digestive Diseases Center, DK067366 and CA116845. The contents of this article are solely the responsibility of the authors and do not necessarily represent the official views of the Veterans Affairs or NIH.

Author information

Authors and Affiliations

  1. Department of Medicine, Michael E. DeBakey Veterans Affairs Medical Center, 2002 Holcombe Boulevard, Houston, 77030, TX, USA

    David Y. Graham

  2. Gastroenterology Unit, Hospital Universitario de La Princesa and Instituto de Investigación Sanitaria Princesa, CIBEREHD, Calle de Diego de Leon 62, Madrid, 28006, Spain

    Javier P. Gisbert

Authors
  1. David Y. Graham
    View author publications

    Search author on:PubMed Google Scholar

  2. Javier P. Gisbert
    View author publications

    Search author on:PubMed Google Scholar

Corresponding author

Correspondence to David Y. Graham.

Ethics declarations

Competing interests

Dr. Graham is a unpaid consultant for Novartis in relation to vaccine development for treatment or prevention of H. pylori infection. Dr. Graham is also a paid consultant for RedHill Biopharma regarding novel H. pylori therapies and for Otsuka Pharmaceuticals regarding diagnostic testing. Dr. Graham has received royalties from Baylor College of Medicine patents covering materials related to 13C-urea breath test. Dr. Gisbert has served as a speaker, a consultant and advisory member for, or has received research funding from Almirall, Janssen-Cilag, Nycomed, and AstraZeneca.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Graham, D., Gisbert, J. Tailored therapy with novel sequential quadruple therapies. Nat Rev Gastroenterol Hepatol 10, 6–8 (2013). https://doi.org/10.1038/nrgastro.2012.232

Download citation

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/nrgastro.2012.232

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing